Pharmacological basis and antifibrotic potential of Zhuang medicine huanggen in hepatic and pulmonary fibrosis
Fibrosis is a dynamic yet a stage that poses therapeutic challenges in chronic liver diseases and other systemic disorders. Huanggen (HG), the dried root of Prismatomeris connata or Prismatomeris tetrandra , has long been used in Zhuang traditional medicine to treat hepatitis, silicosis, rheumatism, and other chronic conditions. Modern studies reveal a diverse chemical profile, including anthraquinones, triterpenes, polysaccharides, and trace organometallics, which contribute to its pharmacological activities. HG exerts antitumor, anti-inflammatory, and antioxidant effects; suppresses hepatic stellate cell activation; inhibits epithelial-mesenchymal transition; and regulates macrophage polarization through modulation of TGF-β/Smad, PI3K/Akt, Nrf2/HO-1 pathways, as well as oxidative stress and immune responses. This review integrates phytochemistry, pharmacology, and mechanistic insights into HG, with a particular focus on its role in hepatic and pulmonary fibrosis, aiming to provide a foundation for the development of novel antifibrotic therapeutics.
Authors
- Mao Chen (ORCID: https://orcid.org/0000-0002-5504-3775)
- Wanrong GuShoubin DongZhizhao Zeng
- Erwei Hao (ORCID: https://orcid.org/0000-0001-7394-6022)
- Zhengcai Du
- Wanchao Hou
- Qianhan Liu
- Kai Yu
- Jinhua Lu
- Jiagang Deng
Institutions
- Guangxi University (CN)
- Guangxi University of Chinese Medicine (CN)
Publication Details
- Journal
- Current Pharmaceutical Analysis
- Published
- 2026-02-10
- DOI
- https://doi.org/10.1016/j.cpan.2026.02.001
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00